Lexicon Pharmaceuticals LXRX Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's change in AP?
- Lexicon Pharmaceuticals (LXRX) reported change in AP of -$6.9M in Q1 2026.
- How has Lexicon Pharmaceuticals's change in AP changed year-over-year?
- Lexicon Pharmaceuticals's change in AP increased by 68.2% year-over-year, from -$21.69M to -$6.9M.
- What is the long-term trend for Lexicon Pharmaceuticals's change in AP?
- Over 2 years (2021 to 2024), Lexicon Pharmaceuticals's change in AP has grown at a -2.1% compound annual growth rate (CAGR), from -$15.43M to $14.8M.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.